No, what could happen is that this is used as a surrogate phase 2 trial for non-covid ARDS to design a trial that has a good chance of success. They can't retrospectively change the covid trial design to repower it.
Covid was not significant for profit compared to non-covid ARDS, so if you're an optimist then there's still some sunshine for the future, I don't think I would necessarily take that view. Personally I have a lot of questions about this that will be answered once there is more data available.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-314
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |